Advertisement
To access the conference call, please dial:
United States toll-free dial-in number: +1.866.510.0704
Please ask to be connected to Simcere's Q2 2008 Earnings Call and providethe following passcode: 25912661. Simcere will also broadcast a live audiowebcast of the conference call. The broadcast will be available by visitingthe "Investor Relations" section of the company's Web site at www.simcere.com.
Advertisement
Following the earnings conference call, an archive of the call will beavailable by dialing:
United States toll-free dial-in number: +1.888.286.8010
The passcode for replay participants is: 83949361. The telephone replayalso will be archived on the "Investor Relations" section of the company's Website at http://www.simcere.com for seven days following the earningsannouncement.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group (NYSE: SCR) is a leading manufacturer andsupplier of branded generic and innovative anti-cancer pharmaceuticals in therapidly growing China market. In recent years, Simcere Pharmaceutical Grouphas focused its strategy on the development of first-to-market generic andinnovative pharmaceuticals, and has introduced a first-to-market genericanti-stroke medication under the brand name Bicun and an innovativeanti-cancer medication under the brand name Endu. It currently manufacturesand sells 39 principal pharmaceutical products including antibiotics,anti-cancer medication and anti-stroke medication and is the exclusivedistributor of three additional pharmaceuticals that are marketed under itsbrand names. Simcere concentrates its research and development efforts on thetreatment of diseases with high incidence and/or mortality rates and for whichthere is a clear demand for more effective pharmacotherapy such as cancer,strokes, osteoporosis and infectious diseases. For more information aboutSimcere Pharmaceutical Group, please visit http://www.simcere.com.United States dial-in number: +1.617.597.5362 China toll-free dial-in number: 10.800.130.0399 Hong Kong dial-in number: +852.3002.1672
SOURCE Simcere Pharmaceutical Group
